WP
ZNTL icon

Woodline Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Woodline Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$623K Sell
266,032
-264,550
-50% -$683K ﹤0.01% 938
2025
Q4 		$716K Hold
530,582
– – ﹤0.01% 868
2025
Q3 		$801K Hold
530,582
– – ﹤0.01% 813
2025
Q2 		$615K Hold
530,582
– – ﹤0.01% 839
2025
Q1 		$844K Hold
530,582
– – 0.01% 781
2024
Q4 		$1.61M Sell
530,582
-524,700
-50% -$1.72M 0.01% 689
2024
Q3 		$3.88M Sell
1,055,282
-461,795
-30% -$1.68M 0.03% 417
2024
Q2 		$6.2M Buy
1,517,077
+80,051
+6% +$894K 0.06% 315
2024
Q1 		$22.6M Buy
1,437,026
+33,473
+2% +$460K 0.21% 150
2023
Q4 		$21.3M Buy
1,403,553
+403,553
+40% +$5.89M 0.23% 130
2023
Q3 		$20.1M Sell
1,000,000
-94,974
-9% -$2.41M 0.24% 129
2023
Q2 		$30.9M Sell
1,094,974
-1,070,577
-49% -$25.7M 0.37% 75
2023
Q1 		$37.2M Buy
2,165,551
+2,019,032
+1,378% +$40.9M 0.51% 46
2022
Q4 		$2.95M Sell
146,519
-173,228
-54% -$3.73M 0.04% 419
2022
Q3 		$6.93M Buy
319,747
+138,475
+76% +$3.79M 0.1% 246
2022
Q2 		$5.09M Buy
181,272
+140,524
+345% +$3.72M 0.08% 259
2022
Q1 		$1.88M Sell
40,748
-327,425
-89% -$17.7M 0.03% 400
2021
Q4 		$30.9M Sell
368,173
-139,674
-28% -$10.8M 0.44% 49
2021
Q3 		$33.8M Buy
507,847
+2,172
+0.4% +$125K 0.55% 43
2021
Q2 		$26.9M Buy
505,675
+361,514
+251% +$19.4M 0.5% 50
2021
Q1 		$6.25M Buy
144,161
+4,161
+3% +$179K 0.14% 170
2020
Q4 		$7.27M Buy
140,000
+2,116
+2% +$95.4K 0.19% 138
2020
Q3 		$4.51M Buy
137,884
+94,158
+215% +$3.3M 0.15% 135
2020
Q2 		$2.1M Buy
+43,726
New +$1.68M 0.08% 133

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Woodline Partners's ZNTL Position: Q1 2026 in Review

Woodline Partners reduced its Zentalis Pharmaceuticals (ZNTL) stake by 50% in Q1 2026, selling an estimated $683K and leaving 266,032 shares worth $623K. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Woodline Partners first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $37.2M in Q1 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Woodline Partners held 266,032 shares of Zentalis Pharmaceuticals worth $623K as of Q1 2026.
  • Woodline Partners sold 264,550 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $683K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #938 holding.
  • Woodline Partners first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Woodline Partners's Zentalis Pharmaceuticals position peaked at $37.2M in Q1 2023.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.